FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $477.65M | ||||
Company | Location |
Date | Amt. (M) |
Details |
Addex |
Geneva |
9/19/06 |
CHF40 |
The Series C round was led by SR One Ltd., and included investments by another new investor, Roche Venture Fund, and existing investors Sofinnova Partners, Index Ventures, TVM Capital, PolyTechnos Venture-Partners, Bio*One Capital Pte. Ltd., Renaissance PME and Varuma AG |
AerovectRx |
Atlanta |
9/8/06 |
ND |
The company's first round of venture financing was led by Georgia Venture Partners Inc., Emergent Growth Fund LLC and the Advanced Technology Development Center Seed Fund |
Alvine |
Palo Alto, Calif. |
9/12/06 |
$21 |
The Series A financing was led by Sofinnova Ventures, and included Prospect Venture Partners, InterWest Partners, Cargill Ventures and Flagship Ventures |
Amicus |
Cranbury, N.J. |
9/14/06 |
$60 |
The Series D financing was led by New Enterprise Associates, and included current investors Canaan Partners, CHL Medical Partners, Frazier Healthcare Ventures, Palo Alto Investors, Prospect Venture Partners, Quaker BioVentures and Radius Ventures, and new investor Och-Ziff Capital Management Group |
Anthera |
San Francisco |
9/13/06 |
$36 |
The company's Series A financing was co-led by VantagePoint Venture Partners and Sofinnova Ventures, and included Pappas Ventures, Mitsubishi International Corp. and A-1 investors Sears Capital Management and SIM Equity |
Artisan |
Framingham, Mass. |
9/6/06 |
$39 |
The Series A financing was led by NGN Capital LLC, and included JAFCO, New Leaf Venture Partners, Bio*One Capital and NovaQuest |
Athenagen |
South San Francisco |
9/28/06 |
$50 |
The Series B financing was co-led by Sanderling Ventures and Clarus Ventures, and included Index Ventures along with existing investors Charter Life Sciences and Astellas Venture Management |
Caden |
Madison, Wis. |
9/6/06 |
$5.85 |
The Series A financing led by Baird Venture Partners, and included Venture Investors, The State of Wisconsin Investment Board, Illinois Ventures LLC and existing investor Vanderbilt University |
Gamida |
Jerusalem |
9/27/06 |
$16 |
The Series D financing was led by Israel Healthcare Ventures, and included existing investors Elscint Biomedical Investment, Denali Ventures, Biomedical Investments and Teva Pharmaceuticals |
Medior Inc. |
Malvern, Pa. |
9/5/06 |
$7 |
The Series A financing was led by Polaris Venture Partners and Morgenthaler Ventures, and inclu- ded HealthCare Ventures and Easton Capital |
Metastatix Inc. |
Atlanta |
9/7/06 |
$3.6 |
The Series A financing was led by H.I.G. Ventures, which was joined by new investors The Aurora Funds, CM Capital, SR One and MedImmune Ventures Inc., and existing investors Georgia Venture Partners and Centrosome Ventures, along with the state of Georgia |
NovaCardia |
San Diego |
9/25/06 |
$48 |
The Series B financing was led by Skyline Ventures, and included InterWest Partners as well as previous investors Domain Associates, Forward Ventures, Montreux Equity Partners and Versant Ventures |
NuPathe Inc. |
Conshohocken, Pa. |
9/13/06 |
$15 |
The Series A financing was co-led by Birchmere Ventures and BioAdvance Ventures, and included funding from Safeguard Scientifics Inc. and others |
Oncalis AG |
Zurich, Switzerland |
9/6/06 |
ND |
The company was spun out of ESBATech AG; funding was provided by ESBAtech investors including Novartis Venture Fund, BioMedinvest and VI Partners |
Pepscan |
Lelystad, the Netherlands |
9/19/06 |
€7 ($8.9) |
The Series B financing with Dutch investors was led by BioX Biosciences BV, and included Lupus Ventures BV, PPM Oost NV and Technofund Flevoland BV |
Prism |
King of Prussia, Pa. |
9/18/06 |
$23 |
The financing was provided by Paul Capital Partners' Paul Royalty Fund II LP and existing investor Essex Woodlands Health Ventures Fund VI; up to $45M more in milestone-based funding could be provided |
RedPath |
Pittsburgh |
9/28/06 |
ND |
The Series A financing was led by NewSpring Capital, and included CID Capital and other investors |
RenaMed |
Westborough, Mass. |
9/7/06 |
$40 |
The mezzanine financing round was led by TVM Capital and Lurie Investments, and included new investors MDS Capital, Merlin BioMed Group, Dow Employees' Pension Plan and TSC BioVenture Capital Corp., and existing investors Apjohn Ventures Fund, BD Ventures, Bio*One Capital and NorthCoast Technology Investors |
Singulex Inc. |
Hayward, Calif. |
9/19/06 |
$10.5 |
The total included an $8M Series C investment that included existing investors Fisk Venture and Prolog Ventures; also, GE Capital made a $1M investment, and Bridge Bank provided a $1.5M debt financing |
Sirion |
Tampa, Fla. |
9/18/06 |
$25 |
Funds affiliated with North Sound Capital LLC provided the funding, in conjunction with the shell company Tenby Pharma Inc.'s acquisition of Sirion |
Zealand |
Glostrup, Denmark |
9/5/06 |
€29 ($36.8) |
The Series D financing was structured as a rights issue for existing investors, which purchased the shares at €5.10 each |
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.